JP2016516068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516068A5 JP2016516068A5 JP2016503207A JP2016503207A JP2016516068A5 JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5 JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- unsubstituted
- aryl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims description 67
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 39
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 39
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 26
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 14
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 10
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000005587 carbonate group Chemical group 0.000 claims description 8
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 8
- 125000004185 ester group Chemical group 0.000 claims description 8
- 125000001033 ether group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000007970 thio esters Chemical group 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 7
- 125000000101 thioether group Chemical group 0.000 claims description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- -1 thioacid group Chemical group 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 3
- 201000011190 diabetic macular edema Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 150000003457 sulfones Chemical class 0.000 claims description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical group CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 44
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004149 thio group Chemical group *S* 0.000 claims 1
- 238000000034 method Methods 0.000 description 60
- 230000036470 plasma concentration Effects 0.000 description 3
- 0 C*N(*)C(*)C(N(*)*(C)C)=O Chemical compound C*N(*)C(*)C(N(*)*(C)C)=O 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792868P | 2013-03-15 | 2013-03-15 | |
| US201361792679P | 2013-03-15 | 2013-03-15 | |
| US61/792,868 | 2013-03-15 | ||
| US61/792,679 | 2013-03-15 | ||
| US201361882056P | 2013-09-25 | 2013-09-25 | |
| US201361882048P | 2013-09-25 | 2013-09-25 | |
| US61/882,048 | 2013-09-25 | ||
| US61/882,056 | 2013-09-25 | ||
| US201461934570P | 2014-01-31 | 2014-01-31 | |
| US61/934,570 | 2014-01-31 | ||
| PCT/US2014/029723 WO2014145068A1 (en) | 2013-03-15 | 2014-03-14 | Compositions, formulations and methods for treating ocular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019147238A Division JP6865254B2 (ja) | 2013-03-15 | 2019-08-09 | 眼疾患を処置するための組成物、製剤、および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516068A JP2016516068A (ja) | 2016-06-02 |
| JP2016516068A5 true JP2016516068A5 (enExample) | 2017-04-20 |
| JP6572201B2 JP6572201B2 (ja) | 2019-09-04 |
Family
ID=51529957
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503207A Active JP6572201B2 (ja) | 2013-03-15 | 2014-03-14 | 眼疾患を処置するための組成物、製剤、および方法 |
| JP2019147238A Active JP6865254B2 (ja) | 2013-03-15 | 2019-08-09 | 眼疾患を処置するための組成物、製剤、および方法 |
| JP2021064106A Active JP7249374B2 (ja) | 2013-03-15 | 2021-04-05 | 眼疾患を処置するための組成物、製剤、および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019147238A Active JP6865254B2 (ja) | 2013-03-15 | 2019-08-09 | 眼疾患を処置するための組成物、製剤、および方法 |
| JP2021064106A Active JP7249374B2 (ja) | 2013-03-15 | 2021-04-05 | 眼疾患を処置するための組成物、製剤、および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (10) | US9440963B2 (enExample) |
| EP (3) | EP4101297A1 (enExample) |
| JP (3) | JP6572201B2 (enExample) |
| KR (1) | KR20150129019A (enExample) |
| CN (2) | CN109925312A (enExample) |
| AU (2) | AU2014233363B2 (enExample) |
| BR (1) | BR112015023753A2 (enExample) |
| CA (1) | CA2903871A1 (enExample) |
| ES (2) | ES2766326T3 (enExample) |
| GB (3) | GB2549865B (enExample) |
| HK (2) | HK1219836A1 (enExample) |
| IL (2) | IL240786B (enExample) |
| MX (1) | MX371382B (enExample) |
| MY (1) | MY171945A (enExample) |
| PH (2) | PH12015502153B1 (enExample) |
| SG (1) | SG11201507131WA (enExample) |
| WO (1) | WO2014145068A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| PL2451279T3 (pl) | 2009-07-06 | 2019-09-30 | Aerpio Therapeutics, Inc. | Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych |
| US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
| EP2493457B1 (en) | 2009-10-30 | 2017-08-09 | IX Biopharma Ltd | Fast dissolving solid dosage form |
| RS54010B1 (sr) | 2009-11-06 | 2015-10-30 | Aerpio Therapeutics Inc. | Inhibitori prolil hidroksilaze |
| US20180092883A1 (en) * | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| EP2648794B1 (en) | 2010-12-08 | 2019-08-28 | ConvaTec Technologies Inc. | Wound exudate system accessory |
| US10207031B2 (en) | 2010-12-08 | 2019-02-19 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| HK1201196A1 (en) | 2011-10-13 | 2015-08-28 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| NZ706302A (en) * | 2012-10-11 | 2017-07-28 | Ix Biopharma Ltd | Sublingual wafer solid dosage form containing amylopectin |
| EP4101297A1 (en) * | 2013-03-15 | 2022-12-14 | Aerpio Pharmaceuticals, Inc. | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| CN106232120B (zh) | 2014-02-19 | 2021-01-08 | 爱尔皮奥治疗有限公司 | 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法 |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| WO2017075814A1 (zh) * | 2015-11-06 | 2017-05-11 | 华为技术有限公司 | 一种语音漫游方法，移动性管理网元及接入网网元 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CN109996440A (zh) * | 2016-10-21 | 2019-07-09 | 曼宁研究有限公司 | Ve-ptp敲除 |
| US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
| AU2020259450A1 (en) * | 2019-04-18 | 2021-11-18 | EyePoint Pharmaceuticals, Inc. | Methods of treating hypertension with activators of Tie-2 |
| WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| GB2589400A (en) * | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
| EP4051267A4 (en) | 2019-10-29 | 2023-12-06 | EyePoint Pharmaceuticals, Inc. | TIE-2 SMALL MOLECULE ACTIVATORS |
| WO2021257754A1 (en) * | 2020-06-16 | 2021-12-23 | Ripka, Amy | Small molecule ve-ptp inhibitors |
| CN116940355A (zh) * | 2020-12-18 | 2023-10-24 | 视点制药公司 | 用于制造tie-2的小分子激活剂的方法 |
| WO2025128706A1 (en) * | 2023-12-11 | 2025-06-19 | Massachusetts Eye And Ear Infirmary | Methods of using tie-2 activators |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078486A (en) | 1989-10-13 | 1992-01-07 | Evans David W | Self-calibrating vision test apparatus |
| US5688781A (en) | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
| EP0821728B1 (en) | 1995-04-06 | 2004-08-11 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligands, methods of making and uses thereof |
| US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
| US6455031B1 (en) * | 1997-06-18 | 2002-09-24 | David G Davies | Methods and compositions for controlling biofilm development |
| US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
| US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| US6455035B1 (en) * | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| CA2368670C (en) | 1999-03-26 | 2012-06-05 | Chitra Suri | Modulation of vascular permeability by means of tie2 receptor activators |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| PL359653A1 (en) | 2000-06-23 | 2004-08-23 | Schering Aktiengesellschaft | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| CN1487935A (zh) * | 2000-12-11 | 2004-04-07 | ����ҩƷ��ҵ��ʽ���� | 改良型水溶性药物组合物 |
| SE518981C2 (sv) | 2000-12-14 | 2002-12-17 | Shl Medical Ab | Autoinjektor |
| US7166435B2 (en) * | 2001-08-06 | 2007-01-23 | The Quigley Corporation | Compositions and methods for reducing the transmissivity of illnesses |
| US20030158199A1 (en) * | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
| AU2003231098A1 (en) | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| JP2006504743A (ja) * | 2002-10-09 | 2006-02-09 | コーザン バイオサイエンシス インコーポレイテッド | 治療製剤 |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| WO2004060373A1 (ja) * | 2002-12-27 | 2004-07-22 | Santen Pharmaceutical Co., Ltd. | 滲出型加齢黄斑変性治療剤 |
| CA2520255C (en) | 2003-04-09 | 2014-07-08 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| RS20150135A1 (sr) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| WO2005118639A1 (en) * | 2004-06-02 | 2005-12-15 | Valtion Teknillinen Tutkimuskeskus | Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| US20080293691A1 (en) | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
| JP5179373B2 (ja) | 2005-12-15 | 2013-04-10 | アストラゼネカ アクチボラグ | 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ |
| TW200800181A (en) * | 2006-02-09 | 2008-01-01 | Sankyo Co | Pharmaceutical composition for anticancer |
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| US8846685B2 (en) * | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| WO2008027013A2 (en) * | 2006-08-29 | 2008-03-06 | National Cancer Centre | Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer |
| EP2076290B1 (en) * | 2006-10-27 | 2016-12-14 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| DK1932558T3 (da) | 2006-12-13 | 2011-09-05 | Shl Group Ab | Autoinjektor |
| CN101678170B (zh) | 2007-03-23 | 2012-05-30 | Shl集团有限责任公司 | 自动注射器 |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| JP4992147B2 (ja) | 2007-07-06 | 2012-08-08 | エス・ホー・エル・グループ・アクチボラゲット | 二重ばねを有するワンショット注射器 |
| US8038649B2 (en) | 2007-09-18 | 2011-10-18 | Shl Group Ab | Automatic injection device with needle insertion |
| WO2009123211A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社資生堂 | 血管の成熟化、正常化又は安定化剤及びしわ防止・改善剤 |
| CN102099069B (zh) | 2008-05-20 | 2013-11-27 | Shl集团有限责任公司 | 用于药物输送装置的装置 |
| WO2009150071A1 (en) | 2008-06-11 | 2009-12-17 | Shl Group Ab | Medicament delivery device |
| KR20110027659A (ko) * | 2008-06-18 | 2011-03-16 | 가부시키가이샤 시세이도 | 림프관의 안정화제 |
| JP4751482B2 (ja) * | 2008-07-22 | 2011-08-17 | 株式会社メニコン | コンタクトレンズ用液剤 |
| EP2378609A1 (en) | 2008-12-22 | 2011-10-19 | Fujikura, Ltd. | Film antenna and method for manufacturing the same |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| AU2011312203C1 (en) | 2009-01-12 | 2016-09-08 | EyePoint Pharmaceuticals, Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| CN109771421A (zh) * | 2009-01-12 | 2019-05-21 | 爱尔皮奥治疗有限公司 | 治疗血管渗漏综合征的方法 |
| PL2451279T3 (pl) | 2009-07-06 | 2019-09-30 | Aerpio Therapeutics, Inc. | Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| TWI393578B (zh) | 2009-07-07 | 2013-04-21 | Shl Group Ab | 注射裝置 |
| TW201105363A (en) * | 2009-07-14 | 2011-02-16 | Univ Yamagata | Eye drop for macular edema treatment |
| RS54010B1 (sr) | 2009-11-06 | 2015-10-30 | Aerpio Therapeutics Inc. | Inhibitori prolil hidroksilaze |
| JP2011201811A (ja) * | 2010-03-25 | 2011-10-13 | Shiseido Co Ltd | Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤 |
| US20110319455A1 (en) | 2010-04-19 | 2011-12-29 | Bruce Steven Klein | Antifungal Treatment |
| CA2797247C (en) * | 2010-04-28 | 2019-10-22 | Sunnybrook Health Sciences Centre | Methods and uses of tie2 binding and/or activating agents |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| WO2012073627A1 (ja) * | 2010-12-02 | 2012-06-07 | 丸善製薬株式会社 | Ｔｉｅ２活性化剤、血管内皮増殖因子（ＶＥＧＦ）阻害剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 |
| CN102532042A (zh) * | 2010-12-30 | 2012-07-04 | 上海医药工业研究院 | 一种芳基脲类化合物、其中间体及其应用 |
| CA2827082A1 (en) * | 2011-02-11 | 2012-08-16 | Psivida Us, Inc. | Methods of treating macular edema using antiedema therapeutics |
| HK1201196A1 (en) | 2011-10-13 | 2015-08-28 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| EP4101297A1 (en) | 2013-03-15 | 2022-12-14 | Aerpio Pharmaceuticals, Inc. | Compositions, formulations and methods for treating ocular diseases |
| US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| CN106232120B (zh) | 2014-02-19 | 2021-01-08 | 爱尔皮奥治疗有限公司 | 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法 |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| US9719135B2 (en) * | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
-
2014
- 2014-03-14 EP EP22171032.0A patent/EP4101297A1/en active Pending
- 2014-03-14 AU AU2014233363A patent/AU2014233363B2/en active Active
- 2014-03-14 MX MX2015011131A patent/MX371382B/es active IP Right Grant
- 2014-03-14 CA CA2903871A patent/CA2903871A1/en not_active Abandoned
- 2014-03-14 BR BR112015023753A patent/BR112015023753A2/pt not_active Application Discontinuation
- 2014-03-14 EP EP14762974.5A patent/EP2967066B1/en active Active
- 2014-03-14 KR KR1020157029411A patent/KR20150129019A/ko not_active Ceased
- 2014-03-14 HK HK16108038.9A patent/HK1219836A1/zh unknown
- 2014-03-14 CN CN201910221542.4A patent/CN109925312A/zh active Pending
- 2014-03-14 ES ES14762974T patent/ES2766326T3/es active Active
- 2014-03-14 GB GB1709419.4A patent/GB2549865B/en active Active
- 2014-03-14 MY MYPI2015002288A patent/MY171945A/en unknown
- 2014-03-14 CN CN201480028572.9A patent/CN105307498B/zh active Active
- 2014-03-14 ES ES19174479T patent/ES2928162T3/es active Active
- 2014-03-14 US US13/999,670 patent/US9440963B2/en active Active
- 2014-03-14 GB GB1411935.8A patent/GB2516561B/en active Active
- 2014-03-14 WO PCT/US2014/029723 patent/WO2014145068A1/en not_active Ceased
- 2014-03-14 SG SG11201507131WA patent/SG11201507131WA/en unknown
- 2014-03-14 HK HK15107185.3A patent/HK1206558A1/xx unknown
- 2014-03-14 EP EP19174479.6A patent/EP3607821B1/en active Active
- 2014-03-14 GB GB1520656.8A patent/GB2540638B/en active Active
- 2014-03-14 JP JP2016503207A patent/JP6572201B2/ja active Active
-
2015
- 2015-08-24 IL IL240786A patent/IL240786B/en active IP Right Grant
- 2015-09-15 PH PH12015502153A patent/PH12015502153B1/en unknown
-
2016
- 2016-04-14 US US15/098,955 patent/US20160220540A1/en not_active Abandoned
- 2016-04-14 US US15/099,161 patent/US20160220541A1/en not_active Abandoned
-
2017
- 2017-02-27 US US15/443,622 patent/US20180022741A1/en not_active Abandoned
- 2017-09-28 AU AU2017235953A patent/AU2017235953B2/en not_active Expired - Fee Related
-
2018
- 2018-04-20 US US15/958,355 patent/US20180237430A1/en not_active Abandoned
- 2018-04-20 US US15/958,346 patent/US20180237429A1/en not_active Abandoned
- 2018-04-20 US US15/958,358 patent/US20180237431A1/en not_active Abandoned
- 2018-05-02 US US15/969,109 patent/US20180251457A1/en not_active Abandoned
-
2019
- 2019-07-11 IL IL267997A patent/IL267997A/en unknown
- 2019-08-09 JP JP2019147238A patent/JP6865254B2/ja active Active
- 2019-09-04 PH PH12019502018A patent/PH12019502018A1/en unknown
-
2020
- 2020-05-29 US US16/888,247 patent/US20200361926A1/en not_active Abandoned
-
2021
- 2021-04-05 JP JP2021064106A patent/JP7249374B2/ja active Active
-
2022
- 2022-03-03 US US17/685,802 patent/US12152023B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516068A5 (enExample) | ||
| Adam et al. | Cyclodextrin-Derived Host Molecules as Reversal Agents for the Neuromuscular Blocker Rocuronium Bromide: Synthesis and Structure− Activity Relationships | |
| JP2018528273A5 (enExample) | ||
| Fernandez et al. | N-Succinyl-(β-alanyl-l-leucyl-l-alanyl-l-leucyl) doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity | |
| US20050085446A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| JP6968921B2 (ja) | 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション | |
| JP2018518537A5 (enExample) | ||
| JP2015503635A (ja) | フマギリン誘導体ｐｈｆ複合体の医薬品配合物 | |
| AU2014273983A1 (en) | Cyclodextrin-based polymers for the therapeutic delivery | |
| JP2010524963A5 (enExample) | ||
| US20220226444A1 (en) | Formulations of fosaprepitant and aprepitant | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| JP2024112842A (ja) | Ｍｃｌ１タンパク質を阻害する化合物を投与するための製剤及び投与量 | |
| JP2020526497A (ja) | 合成バイオコンジュゲート | |
| JP2019511497A5 (enExample) | ||
| US20190142957A1 (en) | Stable compositions of pegylated carfilzomib compounds | |
| JP2017506640A5 (enExample) | ||
| US20070049552A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| JP2013532664A5 (enExample) | ||
| US20180015170A1 (en) | Cyclodextrin-based polymers for therapeutic delivery | |
| JP2018536650A5 (enExample) | ||
| ES2749053T3 (es) | Polimixinas de baja sustitución y sus composiciones | |
| US20210228577A1 (en) | Substituted cyclodextrin-metal complexes and uses thereof | |
| KR20090040299A (ko) | 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물 | |
| CN113164474B (zh) | 维奈托克的水溶性高分子衍生物 |